MCL Literature Feed

High p62 expression predicts poor survival in MCL by upregulating CCND1 transcription via Nrf2, identifying p62 as a novel prognostic biomarker and potential non-BTK/BCL2 therapeutic target.

NGS-detected TP53 mutations are a major clinical risk factor, enabling precise patient stratification to guide initial therapy selection and identify candidates for novel agents.

This real-world study from Colombia confirms the prognostic value of the MIPI score and the survival benefit of autologous stem cell transplant in a Latin American MCL cohort.

Optical genome mapping reveals diverse cryptic CCND1/2 rearrangements in ~10% of MCLs lacking the classic t(11;14), improving diagnosis and identifying high genomic complexity associated with poor outcomes.

Optical genome mapping detects additional clinically significant genomic aberrations in 8% of mantle cell lymphoma cases compared to standard cytogenetics, potentially improving risk stratification.

This large pooled analysis of 1280 trial patients validates progression within 24 months (POD24) as a robust indicator of poor survival, with rituximab maintenance reducing this risk.

In young, fit MCL patients undergoing frontline autotransplant, large clonal hematopoiesis clones (VAF ≥10%) at baseline are a novel biomarker for worse progression-free and overall survival.

This case series reports an incidental MCL diagnosis from a cervical lymph node during thyroid cancer surgery, underscoring the need for thorough pathological evaluation in atypical presentations.

Mantle cell lymphoma can present with prolymphocytic morphology, a diagnostic pitfall mimicking other lymphoproliferative disorders that requires ancillary testing like cyclin D1 IHC for accurate diagnosis.

This study validates a method using electronic health records to define real-world progression in MCL, providing a scalable endpoint that correlates strongly with overall survival for evidence generation.

In high-risk, relapsed/refractory MCL, real-world data shows BTKi plus venetoclax is highly effective, with no added survival benefit from an anti-CD20 monoclonal antibody.

In a retrospective, mixed-histology study including four MCL patients, splenectomy plus chemotherapy improved survival for aggressive lymphomas presenting with primary splenic involvement, suggesting a potential therapeutic role.

Integrated genomic and transcriptomic profiling identifies novel molecular subsets of MCL that predict patient outcomes, paving the way for risk-stratified therapy.

A new CAR-T hematotoxicity score developed for B-ALL, which replaces ferritin with bone marrow burden, highlights the need to refine existing models like CAR-HT used in MCL for disease-specific prediction.

This retrospective Chinese study validates POD24 (progression within 24 months) as a powerful negative prognostic marker and incorporates it into a new model to better risk-stratify relapsed patients.

In a small real-world study of 38 relapsed/refractory MCL patients, zanubrutinib was associated with fewer select adverse events like hypertension and hemorrhage compared to acalabrutinib.

A Mendelian randomization study suggests a causal link between higher abundance of the gut bacterium Holdemania filiformis and a significantly reduced risk of developing mantle cell lymphoma.

In mantle cell lymphoma, MRD assessment is most predictive of survival after four induction cycles, while rapid clearance within two cycles offers no prognostic benefit, guiding risk stratification.

In a real-world US analysis, relapsed/refractory MCL patients receiving CAR-T had longer treatment-free intervals and lower subsequent healthcare costs compared to standard therapies, supporting its earlier use.

A new flow cytometry score incorporating CD19/CD20 ratio, CD200, and CD43 improves diagnostic sensitivity for differentiating MCL from CLL/SLL, a common and critical clinical challenge.

A cross-validated, lymphoma-tailored NGS panel demonstrates high accuracy, providing a framework for implementing standardized genomic testing for prognostication in routine MCL clinical practice.

A real-world Japanese study identified BTK inhibitor-based therapy and length of hospitalization as the main drivers of increased healthcare costs, providing crucial data for health economic planning.

Rituximab maintenance after bendamustine-based therapy in MCL patients is associated with worse outcomes from SARS-CoV-2 infection, highlighting a significant infectious toxicity risk for this common regimen.

A simulation model using 20 years of real-world data establishes a baseline for lifetime treatment trajectories, crucial for evaluating the cost-effectiveness of new targeted therapies in MCL.

This study confirms that low/negative CD200 and lower CD43 expression by flow cytometry reliably distinguish MCL from CLL, improving routine diagnostic accuracy for B-cell lymphoproliferative disorders.

This large Swedish real-world study on limited-stage MCL demonstrates that radiotherapy-containing frontline regimens are associated with excellent long-term outcomes, supporting a curative-intent, less-intensive approach for this rare subset.

This study evaluates the outcomes of Rituximab-Bendamustine (RB) versus the CHASER regimen as induction therapy for transplant-eligible mantle cell lymphoma, informing pre-transplant treatment selection.

This SEER database analysis confirms older age and advanced stage interact to worsen survival, while also identifying widowed marital status as an independent predictor of higher mortality in MCL.

A novel MIPI/CD3 prognostic model using Quantitative Dot Blot to measure T-cell infiltration improves risk stratification, showing high CD3+ T-cells correlate with better outcomes in MCL.

This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.